BioNTech Bet on Cancer Research: The Path from Pandemic Profits to Breakthrough Therapies
Mainz is central to BioNTech's transition from focusing on COVID-19 vaccines to pioneering oncology treatments using mRNA technology. BioNTech's Q4 earnings per share fell to €1.08 from €1.90, and revenue…